Skip to main content

Advertisement

SpringerLink
Log in

Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group

  • Endocrine Tumors
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Pancreatic neuroendocrine tumors (pNETs) are rare heterogeneous tumors that have been steadily increasing in both incidence and prevalence during the past few decades. Pancreatic NETs are categorized as functional (F) or nonfunctional (NF) based on their ability to secrete hormones that elicit clinically relevant symptoms. Specialized diagnostic tests are required for diagnosis. Treatment options are diverse and include surgical resection, intraarterial hepatic therapy, and peptide receptor radionuclide therapy (PRRT). Systemic therapy options include targeted agents as well as chemotherapy when indicated. Diagnosis and management should occur through a collaborative team of health care practitioners well-experienced in managing pNETs. Recent advances in pNET treatment options have led to the development of the Canadian consensus document described in this report. The discussion includes the epidemiology, classification, pathology, clinical presentation and prognosis, imaging and laboratory testing, medical and surgical management, and recommended treatment algorithms for pancreatic neuroendocrine cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Kocha W, Maroun J, Kennecke H, et al. Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group. Curr Oncol. 2010;17:49–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135:1469–92. doi:10.1053/j.gastro.2008.05.047.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Ellison TA, Edil BH. The current management of pancreatic neuroendocrine tumors. Adv Surg 2012;46:283–96.

    Article  PubMed  Google Scholar 

  4. Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011;29:3044–9. doi:10.1200/JCO.2011.35.1817

    Article  PubMed  Google Scholar 

  5. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14:5377–84.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98–119. doi:10.1159/000335591.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Kulke MH, Benson AB III, Bergsland E, et al. Neuroendocrine tumors. J Natl Compr Canc Netw. 2012;10:724–64.

  8. O’Toole D, Salazar R, Falconi M, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology. 2006;84:189–95. doi:10.1159/000098011.

    Article  PubMed  Google Scholar 

  9. Falconi M, Plockinger U, Kwekkeboom DJ, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84:196–211. doi:10.1159/000098012.

    Article  CAS  PubMed  Google Scholar 

  10. Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–3072. doi:10.1200/JCO.2007.15.4377.

    Article  PubMed  Google Scholar 

  11. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis, and recent trend toward improved survival. Ann Oncol. 2008;19:1727–33. doi:10.1093/annonc/mdn351.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Cukier M, Law C, Liu N, et al. Epidemiology and survival of neuroendocrine tumors in Ontario: a 15-year population-based study [abstract]. J Clin Oncol. 2012;30.

  13. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–12. doi:10.1097/MPA.0b013e3181ec124e.

    Article  PubMed  Google Scholar 

  14. Bosman T, Carneiro F, Hruban R, Theise N. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon: IARC Press; 2010. pp. 13–14.

    Google Scholar 

  15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.

    Google Scholar 

  16. Rindi G, Kloppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395–401. doi:10.1007/s00428-006-0250-1.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Rindi G, Kloppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007;451:757–62. doi:10.1007/s00428-007-0452-1.

    Article  CAS  PubMed  Google Scholar 

  18. Tang L, Berlin J, Branton P, et al. Protocol for the examination of specimens from patients with carcinoma of the endocrine pancreas. College of American Pathologists (CAP); 2013. Pancreas Endocrine 3.2.0.1.

  19. Chejfec G, Falkmer S, Grimelius L, et al. Synaptophysin: a new marker for pancreatic neuroendocrine tumors. Am J Surg Pathol. 1987;11:241–7.

    Article  CAS  PubMed  Google Scholar 

  20. Modlin IM, Gustafsson BI, Moss SF, Pavel M, Tsolakis AV, Kidd M. Chromogranin A: biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol. 2010;17:2427–43. doi:10.1245/s10434-010-1006-3.

    Article  PubMed  Google Scholar 

  21. Taupenot L, Harper KL, O’Connor DT. The chromogranin-secretogranin family. N Engl J Med. 2003;348:1134–49. doi:10.1056/NEJMra021405.

    Article  CAS  PubMed  Google Scholar 

  22. Wiedenmann B, Franke WW, Kuhn C, Moll R, Gould VE. Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A. 1986;83:3500–4.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Bridger JM, Kill IR, Lichter P. Association of pKi-67 with satellite DNA of the human genome in early G1 cells. Chromosome Res. 1998;6:13–24.

    Article  CAS  PubMed  Google Scholar 

  24. Bruno S, Darzynkiewicz Z. Cell cycle dependent expression and stability of the nuclear protein detected by Ki-67 antibody in HL-60 cells. Cell Prolif. 1992;25:31–40.

    Article  CAS  PubMed  Google Scholar 

  25. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257:231–7. doi:10.1006/excr.2000.4888.

    Article  CAS  PubMed  Google Scholar 

  26. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182:311–22. doi:10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.

  27. Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300–13. doi:10.1097/PAS.0b013e3181ce1447.

    Article  PubMed  Google Scholar 

  28. Craig J, Cheung M, Law C, Singh S. Ki-67 index variability in neuroendocrine tumors [abstract]. EMSO. 2012; abstract 1158P 2012.

  29. Zerbi A, Falconi M, Rindi G, et al. Clinicopathological features of pancreatic endocrine tumors: a prospective multicenter study in Italy of 297 sporadic cases. Am J Gastroenterol. 2010;105:1421–9. doi:10.1038/ajg.2009.747.

    Article  PubMed  Google Scholar 

  30. Cheslyn-Curtis S, Sitaram V, Williamson RC. Management of nonfunctioning neuroendocrine tumours of the pancreas. Br J Surg. 1993;80:625–7.

    Article  CAS  PubMed  Google Scholar 

  31. Falconi M, Bartsch DK, Eriksson B, et al. ENETS Consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic nonfunctioning tumors. Neuroendocrinology. 2012;95:120–34. doi:10.1159/000335587.

    Article  CAS  PubMed  Google Scholar 

  32. White TJ, Edney JA, Thompson JS, Karrer FW, Moor BJ. Is there a prognostic difference between functional and nonfunctional islet cell tumors? Am J Surg. 1994;168:627–9.

  33. Bettini R, Partelli S, Boninsegna L, et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery. 2011;150:75–82. doi:10.1016/j.surg.2011.02.022.

    Article  PubMed  Google Scholar 

  34. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798–803. doi:10.1158/1078-0432.CCR-08-0734.

    Article  CAS  PubMed  Google Scholar 

  35. Han JH, Kim MH, Moon SH, et al. Clinical characteristics and malignant predictive factors of pancreatic neuroendocrine tumors. Korean J Gastroenterol. 2009;53:98–105.

  36. La RS, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch. 1996;429:323–33.

    Article  Google Scholar 

  37. Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–92. doi:10.1677/erc.1.01017.

    Article  PubMed  Google Scholar 

  38. Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7. doi:10.1200/JCO.2010.33.0688.

    Article  PubMed  Google Scholar 

  39. Singh S, et al. [Abstract] The role of Ki-67 in the prognosis and management of neuroendocrine (NET) patients in a multidisciplinary cancer center. Gastrointestinal Cancers Symposium, 2012; (suppl 4; abstr 184).

  40. Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19:195–211. doi:10.1016/j.beem.2004.11.013.

    Article  PubMed  Google Scholar 

  41. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab. 2007;21:43–68. doi:10.1016/j.beem.2007.01.003.

    Article  CAS  PubMed  Google Scholar 

  42. Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology. 2009;90:167–83. doi:10.1159/000184855.

    Article  CAS  PubMed  Google Scholar 

  43. Figueiredo FA, Giovannini M, Monges G, et al. Pancreatic endocrine tumors: a large single-center experience. Pancreas. 2009;38:936–40. doi:10.1097/MPA.0b013e3181b365db.

    Article  PubMed  Google Scholar 

  44. Jhala NC, Jhala DN, Chhieng DC, Eloubeidi MA, Eltoum IA. Endoscopic ultrasound-guided fine-needle aspiration: a cytopathologist’s perspective. Am J Clin Pathol. 2003;120:351–67. doi:10.1309/MFRF-J0XY-JLN8-NVDP.

    Article  PubMed  Google Scholar 

  45. Kocjan G. Fine-needle aspiration cytology of the pancreas: a guide to the diagnostic approach. Coll Antropol. 2010;34:749–56.

    PubMed  Google Scholar 

  46. Pais SA, Al-Haddad M, Mohamadnejad M, et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest Endosc. 2010;71:1185–93. doi:10.1016/j.gie.2009.12.006.

    Article  PubMed  Google Scholar 

  47. Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011;18(Suppl 1):S27–S51. doi:10.1530/ERC-10-0282.

    Article  CAS  PubMed  Google Scholar 

  48. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16:978–85. doi:10.1158/1078-0432.CCR-09-1759.

    Article  Google Scholar 

  49. Vinik AI, Woltering EA, Warner RR, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713–34. doi:10.1097/MPA.0b013e3181ebaffd.

    Article  PubMed  Google Scholar 

  50. Krausz Y, Freedman N, Rubinstein R, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with (1)(1)(1)In-DTPA-octreotide (OctreoScan(R)). Mol Imaging Biol. 2011;13:583–93. doi:10.1007/s11307-010-0374-1.

    Article  PubMed  Google Scholar 

  51. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med. 2006;36:228–47. doi:10.1053/j.semnuclmed.2006.03.007.

    Article  PubMed  Google Scholar 

  52. Singh S, Law C. Chromogranin A: A sensitive biomarker for the detection and posttreatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2012;6:313–34. doi:10.1586/egh.12.15.

    Article  CAS  PubMed  Google Scholar 

  53. Yao JC, Pavel M, Phan AT, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab. 2011;96:3741–9. doi:10.1210/jc.2011-0666.

    Article  CAS  PubMed  Google Scholar 

  54. Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2011;18(Suppl 1):S17–S25. doi:10.1530/ERC-10-0280.

    Article  CAS  PubMed  Google Scholar 

  55. 55.Panzuto F, Severi C, Cannizzaro R, et al. Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest. 2004;27:6–11.

    Article  CAS  PubMed  Google Scholar 

  56. Raines D, Chester M, Diebold AE, et al. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans. Pancreas. 2012;41:508–11. doi:10.1097/MPA.0b013e318243a0b6.

    Article  CAS  PubMed  Google Scholar 

  57. Rustagi S, Warner RR, Divino CM. Serum pancreastatin: the next predictive neuroendocrine tumor marker. J Surg Oncol. 2013;108:126–8. doi:10.1002/jso.23359.

    Article  CAS  PubMed  Google Scholar 

  58. Kvols LK, Brendtro KL. The North American Neuroendocrine Tumor Society (NANETS) guidelines: mission, goals, and process. Pancreas. 2010;39:705–6. doi:10.1097/MPA.0b013e3181eb7451.

    Article  PubMed  Google Scholar 

  59. Lee LC, Grant CS, Salomao DR, et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery. 2012;152:965–74. doi:10.1016/j.surg.2012.08.038.

    Article  PubMed  Google Scholar 

  60. Libutti SK, Inabnet WB III. Force or stratagem? Surgery. 2012;152:975–6. doi:10.1016/j.surg.2012.08.061.

    Article  PubMed  Google Scholar 

  61. Crippa S, Bassi C, Salvia R, Falconi M, Butturini G, Pederzoli P. Enucleation of pancreatic neoplasms. Br J Surg. 2007;94:1254–9. doi:10.1002/bjs.5833.

    Article  CAS  PubMed  Google Scholar 

  62. Hellman P, Goretzki P, Simon D, Dotzenrath C, Roher HD. Therapeutic experience of 65 cases with organic hyperinsulinism. Langenbecks Arch Surg. 2000;385:329–36.

    Article  CAS  PubMed  Google Scholar 

  63. 63.Park BJ, Alexander HR, Libutti SK, et al. Operative management of islet cell tumors arising in the head of the pancreas. Surgery. 1998;124:1056–61.

    Article  CAS  PubMed  Google Scholar 

  64. Rothmund M, Angelini L, Brunt LM, et al. Surgery for benign insulinoma: an international review. World J Surg. 1990;14:393–8.

    Article  CAS  PubMed  Google Scholar 

  65. Muller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg. 2007;246:966–74. doi:10.1097/SLA.0b013e31815c2ca3.

    Article  PubMed  Google Scholar 

  66. Smith JK, Ng SC, Hill JS, et al. Complications after pancreatectomy for neuroendocrine tumors: a national study. J Surg Res. 2010;163:63–8. doi:10.1016/j.jss.2010.04.017.

    Article  PubMed  Google Scholar 

  67. Abu HM, McPhail MJ, Zeidan BA, Jones CE, Johnson CD, Pearce NW. Aggressive multi-visceral pancreatic resections for locally advanced neuroendocrine tumours. is it worth it? JOP. 2009;10:276–9.

  68. Bonney GK, Gomez D, Rahman SH, et al. Results following surgical resection for malignant pancreatic neuroendocrine tumours: a single institutional experience. JOP. 2008;9:19–25.

  69. 69.Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88–92.

    Article  CAS  PubMed  Google Scholar 

  70. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y. Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg. 1996;20:908–14.

    Article  CAS  PubMed  Google Scholar 

  71. Fendrich V, Langer P, Celik I, et al. An aggressive surgical approach leads to long-term survival in patients with pancreatic endocrine tumors. Ann Surg. 2006;244:845–51. doi:10.1097/01.sla.0000246951.21252.60.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated? Cancer Control. 2008;15:314–21.

    PubMed  Google Scholar 

  73. Kleine M, Schrem H, Vondran FW, Krech T, Klempnauer J, Bektas H. Extended surgery for advanced pancreatic endocrine tumours. Br J Surg. 2012;99:88–94. doi:10.1002/bjs.7681.

    Article  CAS  PubMed  Google Scholar 

  74. Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors. Arch Surg. 2003;138:859–66. doi:10.1001/archsurg.138.8.859.

    Article  PubMed  Google Scholar 

  75. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery. 2002;132:976–82. doi:10.1067/msy.2002.128615.

    Article  PubMed  Google Scholar 

  76. Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL. En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg. 2002;6:147–57.

    Article  PubMed  Google Scholar 

  77. Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg. 1999;3:233–43.

    Article  CAS  PubMed  Google Scholar 

  78. Kouvaraki MA, Solorzano CC, Shapiro SE, et al. Surgical treatment of nonfunctioning pancreatic islet cell tumors. J Surg Oncol. 2005;89:170–85. doi:10.1002/jso.20178.

    Article  PubMed  Google Scholar 

  79. Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8:935–49. doi:10.1016/j.gassur.2004.09.046.

    Article  PubMed  Google Scholar 

  80. Cusati D, Zhang L, Harmsen WS, et al. Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J Am Coll Surg. 2012;215:117–24. doi:10.1016/j.jamcollsurg.2012.05.002.

    Article  PubMed  Google Scholar 

  81. 81.Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432–45.

    Article  CAS  PubMed  Google Scholar 

  82. Hung JS, Chang MC, Lee PH, Tien YW. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases? World J Surg. 2007;31:2392–7. doi:10.1007/s00268-007-9264-3.

    Article  PubMed  Google Scholar 

  83. Saxena A, Chua TC, Perera M, Chu F, Morris DL. Surgical resection of hepatic metastases from neuroendocrine neoplasms: a systematic review. Surg Oncol. 2012;21:e131–41. doi:10.1016/j.suronc.2012.05.001.

    Article  PubMed  Google Scholar 

  84. Mayo SC, de Jong MC, Bloomston M, et al. Surgery versus intraarterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18:3657–65. doi:10.1245/s10434-011-1832-y.

    Article  PubMed  Google Scholar 

  85. Elias D, Sideris L, Liberale G, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery. 2005;137:411–6. doi:10.1016/j.surg.2004.11.007.

    Article  PubMed  Google Scholar 

  86. Elias D, David A, Sourrouille I, et al. Neuroendocrine carcinomas: optimal surgery of peritoneal metastases (and associated intraabdominal metastases). Surgery. 2014;155:5–12. doi:10.1016/j.surg.2013.05.030.

    Article  PubMed  Google Scholar 

  87. Kianmanesh R, Ruszniewski P, Rindi G, et al. ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology. 2010;91:333–40. doi:10.1159/000286700.

    Article  CAS  PubMed  Google Scholar 

  88. Steinmuller T, Kianmanesh R, Falconi M, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87:47–62. doi:10.1159/000111037.

    Article  PubMed  Google Scholar 

  89. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol. 2011;4:29. doi:10.1186/1756-8722-4-29.

    Article  PubMed Central  PubMed  Google Scholar 

  90. Lewis MA, Hobday TJ. Treatment of neuroendocrine tumor liver metastases. Int J Hepatol. 2012;973–946. doi:10.1155/2012/973946.

  91. Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1980;303:1189–94. doi:10.1056/NEJM198011203032101.

    Article  CAS  PubMed  Google Scholar 

  92. Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22:4762–771. doi:10.1200/JCO.2004.04.024.

    Article  CAS  PubMed  Google Scholar 

  93. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326:519–23. doi:10.1056/NEJM199202203260804.

    Article  CAS  PubMed  Google Scholar 

  94. Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011;117:268–75. doi:10.1002/cncr.25425.

    Article  CAS  PubMed  Google Scholar 

  95. Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer. 1999;81:1351–5. doi:10.1038/sj.bjc.6690325.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  96. Hainsworth JD, Spigel DR, Litchy S, Greco FA. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study. J Clin Oncol. 2006;24:3548–54. doi:10.1200/JCO.2005.05.0575.

    Article  CAS  PubMed  Google Scholar 

  97. Sorbye H, Wekin S, Langer S, et al. Ki-67 Proliferative Index Predicts Response to Chemotherapy and Survival in 252 Patients with High-Grade Gastrointestinal Neuroendocrine Carcinoma (WHO G3) (abstract). North American Neuroendocrine Society Symposium, Abstract C36 2012.

  98. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer. 2011;117:4617–22. doi:10.1002/cncr.26124.

    Article  CAS  PubMed  Google Scholar 

  99. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514–23. doi:10.1056/NEJMoa1009290.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  100. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501–13. doi:10.1056/NEJMoa1003825.

    Article  CAS  PubMed  Google Scholar 

  101. 101.Ricke J, Klose KJ, Mignon M, Oberg K, Wiedenmann B. Standardisation of imaging in neuroendocrine tumours: results of a European Delphi process. Eur J Radiol. 2001;37:8–17.

    Article  CAS  PubMed  Google Scholar 

  102. A randomized, double-blind, placebo-controlled study of lanreotide antiproliferative response in patients with gastroenteropancreatic neuroendocrine tumors (CLARINET). The European Cancer Congress; 2013.

  103. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30. doi:10.1200/JCO.2007.15.2553.

    Article  CAS  PubMed  Google Scholar 

  104. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90:220–6. doi:10.1159/000225951.

    Article  CAS  PubMed  Google Scholar 

  105. Sowa-Staszczak A, Pach D, Stefanska A, et al. Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with nonfunctioning neuroendocrine pancreatic tumours? Nucl Med Rev Cent East Eur. 2011;14:73–8.

    Article  PubMed  Google Scholar 

  106. Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol. 2012;30:1100–6. doi:10.1200/JCO.2011.37.2151.

    Article  CAS  PubMed  Google Scholar 

  107. Gulenchyn KY, Yao X, Asa SL, Singh S, Law C. Radionuclide therapy in neuroendocrine tumours: a systematic review. Clin Oncol R Coll Radiol. 2012;24:294–308. doi:10.1016/j.clon.2011.12.003.

    Article  CAS  PubMed  Google Scholar 

  108. 108.Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3:761–71.

    Article  CAS  PubMed  Google Scholar 

  109. Fjallskog ML, Sundin A, Westlin JE, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of alpha-interferon and somatostatin analogs. Med Oncol. 2002;19:35–42. doi:10.1385/MO:19:1:35.

    Article  CAS  PubMed  Google Scholar 

  110. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72. doi:10.1016/S1470-2045(07)70410-2.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

Funding for development, including consensus meeting costs and honoraria, and editorial support have been provided through an unrestricted educational grant from Novartis Pharmaceuticals Canada. Writing and editing assistance was provided by Havas Life Toronto.

Disclosure

There are no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Medicine, Odette Cancer Centre – Sunnybrook Hospital, University of Toronto, Toronto, ON, Canada

    Simron Singh MD, MPH & Calvin Law MD

  2. Department of Medical Imaging, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada

    Chris Dey MD

  3. BC Cancer Agency, Vancouver, BC, Canada

    Hagen Kennecke MD

  4. London Regional Cancer Centre, London, ON, Canada

    Walter Kocha MD

  5. The Ottawa Hospital, Ottawa, ON, Canada

    Jean Maroun MD

  6. McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada

    Peter Metrakos MD

  7. Havas Life Toronto, Toronto, ON, Canada

    Tariq Mukhtar PhD

  8. Department Surgery and Oncology, University of Calgary, Calgary, AB, Canada

    Janice Pasieka MD

  9. Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada

    Daniel Rayson MD

  10. Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Corwyn Rowsell MD

  11. Hopital Maisonneuve-Rosemont, Montreal, QC, Canada

    Lucas Sideris MD

  12. St. Boniface General Hospital, Winnipeg, MB, Canada

    Ralph Wong MD

Authors
  1. Simron Singh MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris Dey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hagen Kennecke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Walter Kocha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean Maroun MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Peter Metrakos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tariq Mukhtar PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Janice Pasieka MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel Rayson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Corwyn Rowsell MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lucas Sideris MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ralph Wong MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Calvin Law MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simron Singh MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S., Dey, C., Kennecke, H. et al. Consensus Recommendations for the Diagnosis and Management of Pancreatic Neuroendocrine Tumors: Guidelines from a Canadian National Expert Group. Ann Surg Oncol 22, 2685–2699 (2015). https://doi.org/10.1245/s10434-014-4145-0

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4145-0

Keywords

Search

Navigation